Published in JAMA Oncology · View the paper (DOI)
The NRG-BR001 trial found SBRT to be safe for patients with multiple metastases, with no dose-limiting toxicities and over 50% of participants alive at 2 years. The study used extensive radiation QA processes and was the first to require 3D image guidance during treatment.
Coverage from 2 institutions